Familial melanoma: genes and variants
Explore variant evidence for Familial melanoma across 4 analyzed proteins (CDKN2A, CDK4, POT1, TERT). Linked ClinVar records include 17 pathogenic or likely pathogenic variants, 557 variants of uncertain significance and 94 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Familial melanoma
CDKN2A: Tumor suppressor ARF
The ARF product of CDKN2A is a tumor-suppressor protein that binds MDM2 and helps preserve p53 activity. By promoting cell-cycle arrest and apoptosis, it provides an important barrier to uncontrolled cell growth from within the nucleolus.
15 ClinVar pathogenic / likely pathogenic and 237 uncertain variants in CDKN2A have source records linked to Familial melanoma. Association strength is not clinical gene validity.
CDK4: Cyclin-dependent kinase 4
Together with D-type cyclins, it phosphorylates RB-family proteins and commits cells to progress from G1 toward DNA replication. Amplification or pathway activation is common in cancer, while rare activating germline variants predispose to familial melanoma.
2 ClinVar pathogenic / likely pathogenic and 414 uncertain variants in CDK4 have source records linked to Familial melanoma. Association strength is not clinical gene validity.
POT1: Protection of telomeres protein 1
It binds the single-stranded ends of telomeres and helps control telomerase access while preventing chromosome ends from being mistaken for DNA breaks. Germline loss-of-function variants predispose to several cancers, including melanoma, glioma, and chronic lymphocytic leukemia, and can produce unusually long telomeres.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in POT1 have source records linked to Familial melanoma. Association strength is not clinical gene validity.
TERT: Telomerase reverse transcriptase
It extends telomeric DNA using an internal RNA template and helps counter progressive chromosome-end shortening in stem and proliferative cells. Loss-of-function variants cause telomere-biology disorders, while promoter activation and increased activity support unlimited proliferation in many cancers.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in TERT have source records linked to Familial melanoma. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): XRCC3.
ClinVar pathogenic and likely pathogenic variants linked to Familial melanoma
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| CDKN2A R99P | 99 | Pathogenic / likely pathogenic (★★) | |
| CDK4 R24C | 24 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| CDK4 R24H | 24 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| CDKN2A G125R | 125 | Pathogenic / likely pathogenic (★★) | |
| CDKN2A R82L | 82 | Pathogenic / likely pathogenic (★★) | |
| CDKN2A R98Q | 98 | Pathogenic / likely pathogenic (★★) | |
| CDKN2A R122L | 122 | Pathogenic / likely pathogenic (★★) | |
| CDKN2A M48I | 48 | Interaction with CDK5RAP3 and MDM2 | Pathogenic / likely pathogenic (★★) |
| CDKN2A G65R | 65 | Pathogenic / likely pathogenic (★★) | |
| CDKN2A D68N | 68 | Pathogenic / likely pathogenic (★★) | |
| CDKN2A A76L | 76 | Pathogenic / likely pathogenic (★★) | |
| CDKN2A R87P | 87 | Pathogenic / likely pathogenic (★★) | |
| CDKN2A G102V | 102 | Pathogenic / likely pathogenic (★★) | |
| CDKN2A P72L | 72 | Pathogenic / likely pathogenic (★★) | |
| CDKN2A P94L | 94 | Pathogenic / likely pathogenic (★★) | |
| CDKN2A P126R | 126 | Pathogenic / likely pathogenic (★★) | |
| CDKN2A G83L | 83 | Pathogenic / likely pathogenic (★) |
Uncertain variants prioritized for review in Familial melanoma
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| CDKN2A R98G | 98 | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; R98Q at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.88 | |
| CDKN2A R98L | 98 | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; R98Q at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.84 | |
| CDKN2A R122Q | 122 | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; R122L at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.98 | |
| CDKN2A R82P | 82 | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; R82L at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.59 | |
| CDKN2A G83S | 83 | Uncertain (★★) | +6: 2 other pathogenic changes within 3 positions; G83L at the same position is pathogenic; seen in 2.7e-06 of gnomAD DNA copies; REVEL 0.652 | |
| CDKN2A R99H | 99 | Uncertain (★★) | +6: 3 other pathogenic changes within 3 positions; R99P at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.68 | |
| CDKN2A R98P | 98 | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; R98Q at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.84 | |
| CDKN2A R82H | 82 | Uncertain (★★) | +6: 2 other pathogenic changes within 3 positions; R82L at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.59 |
Which prediction tools work for Familial melanoma
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- AlphaMissense: 91 out of 100
- PolyPhen-2: 88 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 87 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SIFT: 85 out of 100
- MetaSVM: 77 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 71 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 53 out of 100
Same protein, different disease
- Melanoma-pancreatic cancer syndrome also has ClinVar records linked to CDKN2A variants; they fall in the same places as the Familial melanoma variants (11 pathogenic / likely pathogenic).
- Melanoma, cutaneous malignant also has ClinVar records linked to CDKN2A variants; they fall partly in the same places as the Familial melanoma variants (6 pathogenic / likely pathogenic).
Diseases related to Familial melanoma
- Melanoma, cutaneous malignant, also linked to CDK4, CDKN2A and TERT
- Alzheimer disease, also linked to CDK4 and CDKN2A
- Dyskeratosis congenita, also linked to POT1 and TERT
- Urinary bladder cancer, also linked to CDKN2A and TERT
- Parkinson disease, also linked to CDK4 and CDKN2A
- Lung adenocarcinoma, also linked to CDKN2A and TERT
- Hepatocellular carcinoma, also linked to CDKN2A and TERT
- Acute myeloid leukemia, also linked to TERT
- Non-small cell lung carcinoma, also linked to CDKN2A
- Pulmonary fibrosis and/or bone marrow failure, Telomere-related, also linked to TERT
- Idiopathic pulmonary fibrosis, also linked to TERT
- Melanoma-pancreatic cancer syndrome, also linked to CDKN2A
Frequently asked questions
Which genes have records linked to Familial melanoma?
This view contains 4 analyzed proteins: CDKN2A, CDK4, POT1, TERT. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 17 pathogenic or likely pathogenic variants, 557 variants of uncertain significance and 94 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 8 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 695 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center